Artelo Biosciences, Inc. · NASDAQ:ARTL
Artelo Biosciences — Investor Presentation (September 2026)
25 slides from Artelo Biosciences's investor presentation, September 2026
Slide 1: Corporate Presentation
Q3 2026 Corporate Presentation Pioneering the Science of Lipid Signaling Nasdaq:ARTL Modulation to Develop Novel Therapeutics
Slide 2: Forward Looking Statements
Forward Looking Statements Artelo Biosciences, Inc. (the “Company”) cautions you that statements contained in this presentation regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company’s current beliefs and expectations. Such forward-l
Slide 3: Corporate Highlights
Corporate Highlights Artelo Biosciences is a clinical-stage biopharmaceutical company advancing a broad platform of lipid signaling modulation drug candidates to treat pain, cancer, anxiety, depression, and other conditions $B NOVEL SCIENCE NEAR-TERM BILLION DOLLAR ROBUST PATENT PROVEN PORTFOLIO CAT
Slide 4: Pipeline
Pipeline Multiple value-driving milestones expected over the next 12 -18 months DEVELOPMENT PROGRAM PRECLINICAL Phase 1 Phase 2 Phase 3 ORIGINAL DEVELOPER ART27.13 Dual Cannabinoid Receptor Agonist Cancer-Related Anorexia (Weight Loss) Cancer-Related Cachexia (Muscle Wasting) Glaucoma ART26.12 FABP5
Slide 5: ART27.13
ART27.13 Dual Cannabinoid Receptor Agonist for Cancer-Related Anorexia and Cachexia
Slide 6: ART27.13 Addressing a Significant Need
ART27.13 Addressing a Significant Need Target Indication: Cancer Anorexia Cachexia Syndrome (CACS) CACS is marked by a loss of appetite and weight loss, along with a reduction in muscle mass and fatty tissues affecting up to 80% of advanced cancer patients* with no FDA-approved treatment “ When you
Slide 7: ART27.13 Dual Cannabinoid Receptor Agonist
ART27.13 Dual Cannabinoid Receptor Agonist The many effects of peripheral CB1 activation in promoting appetite, food storage and weight gain GI System Fat Tissue ART27.13 • Increases fat cell differentiation Oral Cavity • Increases fat storage • Increases sweet sensitivity • Decreases mitochondrial
Slide 8: ART27.13 The CAReS Trial
ART27.13 The CAReS Trial Establishing safety, optimal dose, and proof-of-concept in cancer patients with anorexia Phase 1 (Completed) Phase 2 (Interim data announced) Cancer patients with anorexia Cancer patients with anorexia N=24 (6 per dose level) N=40 (3:1 randomization) 12 weeks treatment with
Slide 9: CAReS Safety Results
CAReS Safety Results Phase 1: 27 patients received at least one dose of Phase 2: At interim analysis, 25 patients had ART27.13. No events considered as dose limiting received at least one dose of ART27.13. Seven toxicities and no fatal AEs related to trial treatment. (32%) had AEs considered related
Slide 10: ART27.13 CAReS Phase 2 Results
ART27.13 CAReS Phase 2 Results CAReS inclusion criteria required a documented >5% weight loss during the prior 6 months Weight changes pre-, during and post-treatment ART27.13 dosing period up to 12 weeks (90 days) Duration of safety follow up up to 4 weeks (30 days) CAReS = Cancer Appetite Recovery
Slide 11: ART27.13 CAReS Phase 2 Results
ART27.13 CAReS Phase 2 Results Efficacy versus placebo in lean body mass, weight gain, activity, and well-tolerated up to 1300 μg per day Change in Weight Change in Activity At end of treatment there was an average 6% increase in Activity data captured by MotionWatch showed an weight in patients who
Slide 12: ART27.13 The DREAM Trial
ART27.13 The DREAM Trial Establishing safety, optimal dose, and PoC in glaucoma patients with an increased IOP • Cannabinoids have been shown to reduce IOP (CB1) and may offer neuroprotection (CB2) in glaucoma • Centrally-active cannabinoids targeting CB1 (THC) can induce treatment-limiting CNS side
Slide 13: ART26.12
ART26.12 Fatty Acid Binding Protein 5 (FABP5) Inhibitor
Slide 14: FABP Inhibitor Platform
FABP Inhibitor Platform Fatty Acid Binding Proteins are a validated target with potential in multiple therapeutic areas. Artelo has a worldwide exclusive license from Stony Brook University, NY for multiple generations of FABP inhibitors. Anxiety Dermatology • Psoriasis Disorders • Generalized Anxie
Slide 15: ART26.12 Our Lead FABP5 Inhibitor
ART26.12 Our Lead FABP5 Inhibitor Target Indication: Chemotherapy-Induced Peripheral Neuropathy (CIPN) CIPN affects up to 40% of all treated cancer patients* and is marked by extreme nerve pain causing delays, disruption or discontinuation of essential cancer treatment with no currently available FD
Slide 16: ART26.12 Strong Pre-Clinical Evidence from Multiple Studies
ART26.12 Strong Pre-Clinical Evidence from Multiple Studies Evidence from five animal studies in peripheral neuropathy with ART26.12 supports Artelo’s development strategy for the FABP5 inhibitor as a potential preventative therapeutic for CIPN ART26.12 administered as a prophylactic dose of Oxalipl
Slide 17: ART26.12 Phase 1 Study Results
ART26.12 Phase 1 Study Results The Phase 1 Single Ascending Dose (SAD) & Food Effect (FE) study was designed to assess the safety, tolerability, and pharmacokinetics of ART26.12 in healthy volunteers. The SAD/FE study enrolled 55 subjects. Clinical data from completed SAD and Study Design preliminar
Slide 18: ART12.11 CBD:TMP Cocrystal
Artelo 4 ka i er ei AS _ aed) Pe] ART12.11 CBD:TMP Cocrystal VAY —
Slide 19: ART12.11 CBD:TMP Cocrystal
ART12.11 CBD:TMP Cocrystal Target indication: Anxiety/Depression Anxiety and depression affects about 20% of adults in the US* and is often characterized by feelings of sadness, hopelessness, worry, or dread Proprietary CBD:TMP Cocrystal is a combination drug candidate with improved physical propert
Slide 20: ART12.11 Multiple Competitive Advantages
ART12.11 Multiple Competitive Advantages CBD:TMP cocrystal solved inherent challenges with CBD in accordance with FDA Guidance ART12.11 CBD TMP DRUG COFORMER CBD:TMP COCRYSTAL Physical Properties Pharmacokinetics Pharmacodynamics Patent Estate Developed as an oral solid Delivers higher plasma levels
Slide 21: ART12.11 Promising Anxiety and Depression Data
ART12.11 Promising Anxiety and Depression Data Superior preclinical efficacy observed in stress-induced anxiety model compared to CBD-alone Clinical ART12.11 CBD-alone Behavioral Test Behavior (3.5 mg/kg CBD + 1.5 mg/kg TMP orally dosed) (10 mg/kg orally dosed) Elevated plus maze Anxiety Light-dark
Slide 22: Leadership
Leadership Proven track record of value creation for shareholders Connie Matsui Gregory Gorgas Chair of the Board Iwoa Ojima, PhD President & CEO, Director Wells Fargo, Biogen IDEC, Sutro Biogen IDEC, Chiron, Cetus, Distinguished Professor, Chemistry, Biopharma, Halozyme and Director, Institute of C
Slide 23: Company Capitalization
Company Capitalization Capitalization (as of 8/31/2026, except as noted) Common Shares Outstanding 540,667 Warrants (WAEP $37.16) 784,424 Options (Exercisable options WAEP $250.47) 22,835 Total 1,347,926 Cash, Cash Equivalents, and Marketable Securities (as of 6/30/2026) $4.2M Fully diluted ownershi
Slide 24: Artelo Biosciences Summary
Artelo Biosciences Summary $B NOVEL SCIENCE NEAR-TERM BILLION DOLLAR ROBUST PROVEN PORTFOLIO MILESTONES MARKETS PATENT ESTATE LEADERSHIP • CIPN $2B+ 27 patents issued Experienced team • ART27.13 Dual • ART27.13 Glaucoma 58 patents pending of biopharmaceutical cannabinoid receptor Phase 2 • Cancer an
Slide 25: Investor Relations
artelo-biosciences-inc artelo-biosciences-inc @ArteloBio @ArteloBio INVESTOR RELATIONS (212) 671-1020 ARTL@crescendo-ir.com Nasdaq:ARTL artelobio.com
Artelo Biosciences — Investor Presentation (September 2026) on 6ix